螺旋环化合物:在对抗Mycobacterium tuberculosis的斗争中,潜在的药物领先
Pardeep Kumar1, Anuradha Singampalli1, Rani Bandela1
1Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Future medicinal chemistry
|March 19, 2025
概括
新的螺旋环化合物显示出对抗结核病 (TB) 的前景. 本综述强调了它们的合成和抗结核活性,为开发更安全,更有效的结核病药物提供了潜力.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 有机合成 有机合成
背景情况:
- 结核病 (TB) 仍然是一个全球卫生危机,随着耐药性 (MDR-TB,XDR-TB) 的增加,需要新的治疗策略.
- 螺旋环化合物由于其多功能结构和多样化的生物活动,在药物化学中越来越突出.
- 迫切需要新的抗结核药物来解决每年数百万人死亡的问题.
研究的目的:
- 审查螺旋环化合物的合成和抗结核活性.
- 从2004年到2024年,探索用于结核病治疗的螺旋化合物研究的进展.
- 为设计改进的螺旋环抗结核病剂提供见解.
主要方法:
- 对具有抗结核性质的合成和天然存在的螺旋环化合物的文献综述.
- 分析结构-活动关系和生物数据.
- 检查结核病中螺旋化合物开发的最新研究趋势.
主要成果:
- 合成和天然的螺旋化合物都表现出显著的抗结核性质.
- 某些螺旋环基支架显示出进一步发展成为强效抗结核病药物的前景.
- 研究表明,有可能改善药理动力学和药理动力学特征.
结论:
- 螺旋环化合物是开发新型抗结核病药物的宝贵支架.
- 需要进一步的研究来优化这些化合物,以提高有效性,安全性和新的作用机制.
- 这一审查为抗击结核病的合理药物设计提供了基础.
相关概念视频
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Structure-Activity Relationships and Drug Design
471
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
471
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cycloaddition Reactions: Overview
2.5K
Cycloadditions are one of the most valuable and effective synthesis routes to form cyclic compounds. These are concerted pericyclic reactions between two unsaturated compounds resulting in a cyclic product with two new σ bonds formed at the expense of π bonds. The [4 + 2] cycloaddition, known as the Diels–Alder reaction, is the most common. The other example is a [2 + 2] cycloaddition.
2.5K


![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)